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Summary 
In the present study, an attempt was made to characterize the immunomodulating abilities of the 
cytostatic drugs cydophosphamide, ifosfamide, vinblastine, vincristine, procarbazine, dacar-
bazine, 6-mercaptopurine, methotrexate, 5-f/uor-uracil and adriamycine in a defined experimen-
tal model. Varying combinations of drug plus transplantation alloantigen, (C3H-lymphocytes) 
were injected into Balb/c mice at different time intervals in vivo. The resulting T-effector cell 
reactivity was determined in vitro with the microcytotoxicity assay on day + 5 for primary (r) and 
day + 7 for secondary (2°) sensitized mice. According to the type of drug (alkylating agent vs. vinca 
alkaloid vs. antimetabolite vs. cytostatic antibiotic), the dosage (20% LD50 vs. 60% LD50), the 
state of sensitization (r vs. 2° sensitized recipients), and the time of drug application in relation to 
the antigen treatment on day 0 (in varying steps from day -6 to day +4), so-called "pharmacon-
antigen-variation-effects" (PA VE) were established for each of the investigated drugs in form of 
reaction profiles. 
The results were as folIows: (1) For almost alt substances, characteristic reaction profiles involving 
immunostimulation and/or immunosuppression could be established. Similarities in the profiles of 
different substances made it possible to classify the drugs according to different reaction types. The 
reaction type however is not definitely correlated to the biochemical mechanism of drug action. (2) 
The PA VE are decisively inf/uenced by so me of the biological parameters, such as the time of drug 
application in relation to the antigen treatment and the state of sensitization but relatively !ittle by 
the dosage of the drug. (3) Considering the different processes occurring du ring primary and se-
condary immune responses, the PAVE may give hints for a distinct manipulation of the im-
munoregulation and thus information on the immunobiological mechanism of drug action. 
Introduction 
Classic cytostatic drugs as cyclophosphamide, 
azathioprine or methotrexate have gene rally 
been used as immunosuppressive agents in the 
treatment of autoimmune diseases, graft rejec-
ti on reactions or in tumor chemotherapy. 
However, some years ago several authors 
(Müller-Ruchholtz, 1974; Röllinghoff et al., 
1977) published results showing that under 
certain experimental conditions these drugs 
may not only cause immunosuppression but 
also immunostimulation; thus, these drugs 
could more appropriately be called "im-
munomodulators". Only very recently has 
the immunobiological mode of action of these 
drugs become the focus of more intensive re-
search as was shown by the lively discussion 
on the new substance cyclosporin A 
(Tutschka, 1979; Thomson, 1983). Increasing 
interest in immunopharmacological questions 
however revealed the uncertainty in handling 
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immunomodulating agents and the lack of 
knowledge about their underlying Im-
munobiological mode(s) of action. 
Single calls have been made for systematic ex-
perimental research (e. g. M älter, 1980) and 
Hadden et al. (1981) have particularly stressed 
the following problems: (1) In contrast 
to precise knowledge of the biochemical 
mechanism, the immunobiological mecha-
nism of most of these substances is largely 
unknown. This deficit should be over-
come, also in the interest of research on cell-
mediated immunoregulation. (2) Animal ex-
periments involving immunopharmacological 
agents are performed almost exclusively with 
primary sensitized organisms. The results of 
such experiments however are not transferable 
to the clinical situation, in which immunosup-
pressive treatment generally must presuppose 
astate of secondary sensitization. Therefore 
comparative studies of this essential biological 
parameter appear to be necessary. (3) For the 
increasing number of substances investigated a 
great number of unique and sometimes con-
tradictory results are reported. Reasons for 
this are great differences in the mode of appli-
cation of the drug, its dosage, the type and 
preparation of antigens used and last not least 
the test methods, all of which limit a direct 
comparison of the results. 
Considering the present state of research, it 
becomes obvious how necessary systematic 
comparative experimental studies on drug 
manipulated immune reactivity are, which so 
far have only been presented by Berenbaum 
(1979) for the B-cell system. The present 
study tries to characterize and to compare the 
immunomodulating abilities of a variety of 
clinically used cytostatic drugs on the T -cell 
system in a defined experimental mouse 
model. Therefore so-called "pharmacon-anti-
gen-variation-effects" (PA VE) were estab-
lished for each of the investigated drugs in 
form of reaction profiles. The following ques-
tions were of particular interest: (1) How are 
the immunomodulating effects determined by 
the biochemical type of drug? (2) How are 
such effects influenced by the time and dosage 
of drug application and the state of sensitiza-
tion of the recipient? (3) Do the results ob-
tained from (1) and (2) elucidate the underly-
ing immunobiological mechanism of drug ac-
tion? 
Material and Methods 
Animals 
The experiments were carried out with 2-3 
month old inbred fern ale Balb/c mice (H-2d), 
weighing 22-30 g. 
S ensitization 
2-3 month old inbred female C3H mice (H-
2k) served as alloantigen donors. 5 x 107 sp-
leen, thymus and lymph node cells, suspended 
in Hanks' balanced salt solution (HBSS) were 
injected i. p .. Primary (n sensitized mice re-
ceived only one antigen injection on day 0, 
secondary (2°) sensitized mice two additional 
injections on day -17 and day -10. 
Drugs 
T 0 allow for a direct comparison of the re-
sults, the LDso for female Balb/c mice was de-
termined for each drug separately according to 
the method of Reed and Muench (1938). 
Cyclophosphamide, CY, (Endoxan, Asta-
Werke, Bielefeld): 100 mg CY and 45 mg 
NaCI were dissolved according to the pre-
scription. The injection solution was equilib-
rated with HBSS to 0.5 ml per 20 g body 
weight and injected i.p. within 30 min after 
preparation of the solution. 20% LDso = 102 
mg, and 60% LDso = 306 mg per kg body 
weight (BW). 
Ifosfamide, IF, (Holoxan, Asta-Werke, 
Bielefeld): 200 mg IF; for preparation cf. Cy. 
20% LDso = 118 mg, and 60% LDso = 354 
mg/kgBW. 
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Vinblastine, VLB, (Velbe, E. Lilly GmbH, 
Gießen): 10 mg VLB sulphate; for preparation 
cf. CY. 20% LDso = 1.5 mg, and 60% LDso = 
4.4 mg/kg BW. 
Vincristine, VCR, (LiIly, E. LiIly GmbH, 
Gießen): 1 mg VCR sulphate and 10 mg lac-
tose; for preparation cf. CY. 20% LDso = 0.9 
mg, and 60% LDso = 2.6 mg/kg BW. 
Procarbazine, PC, (Natulan, Hoffmann-La 
Roche, Basel): PC was dissolved in distiIled 
water; for preparation cf. CY. 20% LDso = 
113 mg, and 60% LDso = 339 mg/kg BW. 
Dacarbazine, DTIC, (DTIC-Dome, Miles 
GmbH, Frankfurt): 200 mg DTIC, 200 mg 
citric acid and 75 mg mannit; for preparation 
cf. CY. 20% LDso = 57 mg, and 60% LDso = 
171 mg/kg BW. 
6-Mercaptopurine, 6-MP, (Puri -N etuol, 
Deutsche WeIlcome, Burgwedel): 6-MP was 
dissolved in 0.12% NaOH; for preparation 
cf. CY. 20% LDso = 33 mg, and 60% LDso = 
99 mg/kgBW. 
Methotrexate, MTX, (Methotrexat, Lederle, 
München): 50 mg MTX and 4.8 mg NaCI; for 
preparation cf. CY. 20% LDso = 38 mg, and 
60% LDso = 115 mg/kg BW. 
5-Fluor-Uracil, FU, (Hoffmann-La Roche, 
Basel): 250 mg FU; for preparation cf. CY. 
20% LDso = 68 mg, and 60% LDso = 204 mgl 
kgBW. 
Adriamycine, AM, (Adriblastin, Farmitalia, 
Freiburg): 10 mg AM and 50 mg lactose; for 
preparation cf. CY. 20% LDso = 4 mg, and 
60% LDso = 12 mg/kg BW. 
Each Balb/c mouse received only one single 
drug injection (i. p.). 
Combined treatment 
To determine the immunomodulating abilities 
of the drugs, varying combinations of drug 
plus aIloantigen were injected in vivo into 
Balb/c mice. The resulting "pharmacon-anti-
gen-variation-effects" of the T -effector ceIls 
were determined in vitro according to the type 
of drug (alkylating agent vs. vinca alkaloid vs. 
antimetabolite vs. cytostatic antibiotic), the 
dosage (20% LDso vs. 60% LDso), the state of 
sensitization (1° vs. 2° sensitized recipients), 
and the time of drug application in relation to 
the aIloantigen treatment on day 0 (in varying 
steps from day -6 to day +4). Test time was 
day + 5 for 1 ° and day + 7 for 2° sensitized 
mice (Bräcker et al., 1977). Mice receiving only 
antigen treatment served as controls. 
Test procedure 
For preparation of the target ceIl cultures and 
the T -effector ceIls and for the test procedure, 
cf. Takasugi and Klein 1970. Briefly, 
cytotoxic T -effector spleen ceIls from mice 
treated with drug and antigen, or only antigen 
were co-incubated with adherent target fib-
roblasts for 48 hin Terasaki microtest plates. 
The lysis of the target ceIls was read micros-
copicaIly and calculated for each of the eight 
effector/target ceIl ratios (3:1-400:1) accord-
ing to the foIlowing formula: 
specific lysis (%) = 
(
1 remaining target ceIls (exp.) ) 
target ceIls (con tr. ) 
Results 
1. Primary sensitization 
x 100. 
Figure 1 shows the "pharmacon-antigen-vari-
ation-effects" for the T -effector ceIl reactivity 
of 1° sensitized Balb/c mice which received a 
single dose of aUoantigen on day o. In addition 
they received a single dose of one of the cyto-
static drugs varying from the 6th. day before 
to the 4th. day after the antigen. Two diffe-
rent dosages were applied, 20% and 60% of 
the LDso• The T -effector ceU reactivity of 
spleen lymphocytes was tested with the mic-
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Fig, 1: "Pharmacon-antigen-variation-effects" in primary 
(1°) sensitized Balb/c mice: T -effector cell reactivity of 
spleen lymphocytes after a single injection of the drug 
(60% LDso : -; 20% LDso : ,-,-,-) at varyingdays before, 
with and after treatment with alloantigen on day 0, Mice 
receiving only alloantigen served as controls, 
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rocytotoxicity assay on day +5, the time of 
maximum reactivity of the untreated control 
group. In the following a short description 
will be given, analyzing the essential points of 
the reaction profiles of each of the investigated 
ten drugs. 
Cyclophosphamide: 
The reaction profile shows the form of an "in-
verted S shape" with strong stimulation when 
CY is applied before and strong suppression 
when applied with or after the antigen. The 
two dosages exert only a slight effect on the 
degree of stimulation. 
Ifosfamide: 
The reaction profile resembles that of the re-
lated substance CY, but with stronger sup-
pression when IF is applied with and after the 
antigen. Compared to CY there are marked 
dose-dependent differences in the stimulation 
phase. 
Vinblastine: 
VLB has only a slight influence on T -effector 
ceIl reactivity when applied before or with the 
antigen. Ir causes a strong dose-dependent 
suppression when applied after the antigen. 
Vincristine: 
The reaction profile of VCR is very similar to 
that of the reIated alkaloid VLB: no significant 
immunomodulation in the phase before and 
strong dose-dependent suppression in the 
phase after the antigen. 
Procarbazine: 
PC produces a "bell-shaped" reaction profile 
with definite suppression when applied before 
and after but almost indifferent reactivity 
when applied shortly before or with the anti-
gen. There is a dose-dependent difference in 
the level of the reactivity for most of the inves-
tigated days. 
Dacarbazine: 
DTIC exerts no characteristic modulating ef-
feet on T -effector ceU reactivity. During the 
entire period of investigation, the curve rises 
gradually from strong suppression before to 
weak suppression after the antigen, without 
significant dependence on the dosage. 
6-Mercaptopurine: 
Application of 60% of the LDso results in 
weak to medium stimulation before and with 
and moderate suppression after the antigen. 
The reaction profile for the 20% of the LDso is 
almost a mirror image of this with weak sup-
pression before and with the antigen, but par-
tial stimulation after the antigen. For the first 
time not only quantitative, but also profound 
qualitative, dose-dependent differences occur 
in areaction profile. 
Methotrexate: 
MTX has areaction profile very similar to 
those of CY and IF ("inverted S shape") with 
significant stimulation before and with and 
very strong suppression after the antigen. 
There is no dose-dependence. 
5-Fluor-Uracil: 
FU produces a "bell-like" reaction profile 
with weak suppression before, indifferent 
reactivity with and strong suppression when 
applied after the antigen. The lower dosage 
causes a significant difference in the level of 
reactivity with an otherwise identical reaction 
profile. 
Adriamycine: 
AM influences the reacttvlty only slightly 
when applied before, but exerts medium to 
strong suppression when applied with or after 
the antigen. Pronounced dose-dependent dif-
ferences are seen when it is applied shortly be-
fore and with the antigen. 
2. Secondary sensitization 
Figure 2 shows the PA VE for T -effector ceIl 
reactivity of 2° sensitized Balb/c mice. In addi-
tion to the treatment protocol described above 
the animals received two identical immuniza-
tions with C3H lymphocytes at a week's in-
terval (on day 17 and -10) before re-im-
munization with the antigen on day O. T -ef-
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Fig. 2: "Pharmacon-antigen-variation-effects" in sec on-
dary (2°) sensitized Balb/c mice: T-effector cell reactivity 
of spleen Iymphocytes after a single injection of the drug 
(60% LDso) at varying days before, with and after re-
stimulation with alloantigen on day o. Mice receiving only 
alloantigen served as controls. 
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fector ceIl reactivity was tested on day + 7, the 
time of maximum reactivity of the untreated 
control group. 
Cyclophosphamide: 
In comparison with the reaction profile for 10 
sensitization, the stimulation before and with 
the antigen is more time-limited and the sup-
pression after the antigen is less severe. In con-
trast to the reaction profile described above, 
there is a strong suppression on day -6 
shortly after the last presensitization (the so-
caIled "post 10 sensitization phenomenon"). 
Ifosfamide: 
In comparison with the reaction profile for 10 
sensitization one observes a totaIly different 
curve with "intrasuppressive" modulation. 
With the exception of day 0, the profile may 
be described as an "inverted bell-shape". 
Vinblastine: 
In contrast to the reaction profile for 1 0 sen-
sitization, no significant modulation of the 20 
immune reactivity occurs during the entire 
period of investigation. 
Vincristine: 
In correspondance with VLB we find indiffe-
rent reactivity, whether VCR is applied be-
fore, with or after the antigen. VCR appears to 
be ineffective in modulating 20 immune reac-
tivity. 
Procarbazine: 
Compared with the reaction profile for 10 sen-
sitization the "bell shape" is reversed, i.e., 
medium to weak suppression occurs before 
and after and strong suppression when PC is 
applied with the antigen. 
Dacarbazine: 
The re action profile for 20 sensItlzation is 
similar to that of 10 sensitization with immune 
reactivity rising from strong suppression be-
fore to indifferent reactivity when DTIC is 
applied after the antigen. On days -6 and -4 
there appears presumably a "post 10 sensitiza-
tion phenomenon. " 
6-Mercaptopurine: 
Similar to the reaction profile for 10 sensitiza-
tion, we find an "inverted S shape" with weak 
to medium suppression before and medium to 
strong suppression after the antigen. 
Methotrexate: 
As for 10 sensitization, stimulation is observed 
before, suppression with and after the antigen. 
Both however, are less pronounced. The reac-
tion profile resembles the "inverted S shape" 
of CY, IF and 6-MP. 
5-Fluor-Uracil: 
In comparison to the profile of 10 sensitiza-
tion, FU 20 causes astronger "intrasuppres-
sive modulation". The reaction profile might 
also be described as an "inverted bell shape". 
Adriamycine: 
AM 20 shows areaction profile with very 
strong stimulation before, indifferent reactiv-
ity with and medium suppression when 
applied after the antigen. The reaction profile 
resembles those of CY, IF, MTX and 6-MP in 
10 sensitized mice; it is, however, remarkably 
different from that of AM in 1° sensitized ani-
mals. 
3. Classification of the reaction profiles ac-
cording to reaction types 
On the basis of similarities between the reac-
tion profiles of different drugs, an attempt was 
made to classify the substances with corres-
ponding curves according to different reaction 
types. Regarding the reactivity before, with 
and after the antigen treatment on day 0, all 
reaction profiles can be classified according to 
one of the following 6 types (T able 1): 
Type 1- the "inverted S shape":It is charac-
terized by strong stimulation before and 
strong suppression after the antigen, but 
mainly indifferent reactivity when the drug is 
applied together with the antigen. It occurs 
with CY 00), IF (1°), 6-MP (1°, 2°), MTX 00, 
2°), and AM (2°). 
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Table 1 Classification of the reaction profiles of a 
variety of drugs (abbreviations see text) in 
1 ° and 2° sensitized Balb/c mice into six 
reaction types depending on the modulation 
of immune reactivity before, with and after 
alloantigen treatment 
Type 1 before +++ CY 1°, MTX 1°, 2° 
~ with IF 1°, AM 2° after --- 6-MP 1°, 2° 
Type2 before 0 VLB 1° 
with 0 VCR 1°, AM 1° ~ after --
Type3 before 0 VLB2° 
with 0 VCR2° 
after 0 
Type4 before -- PC1°,FU1° 
/\ with + CY2° after --
Type 5 before - PC2° 
\/ with IF 2°, FU 2° after -
Type 6 before --
with DTIC 1°, 2° 
~ after 0 
Type II - a "horizontalline with a downward 
bend": There is indifferent reactivity when the 
drug is applied before and with but increasing 
suppression when applied after the antigen. It 
occurs with VLB (10) and VCR 00) and less 
pronounced with AM (1°). 
Type III - a "horizontalline" : There is indiffe-
rent reactivity during the entire period of in-
vestigation. It occurs with VLB (2°) and VCR 
(2°). 
Type IV - the "bell shape": It is characterized 
by suppression before and after and indiffe-
rent reactivity to weak stimulation when the 
drug is applied with the antigen. Examples are 
PC (1°), CY (2°) and FU (1°). 
Type V - the "inverted bell shape": It is 
characterized by weak suppression before and 
after and strong suppression when the drug is 
applied with the antigen. It occurs with PC 
(2°) and less pronounced with IF (2°) and FU 
(2°). 
Type VI - an "intrasuppressively rising line": 
It is characterized by strong suppression be-
fore, moderate suppression with and weak 
suppression when the drug is applied after the 
antigen. It occurs only with DTIC (1°, 2°). 
Discussion 
In contrast to considerable knowledge about 
the network of cell-mediated immunoregula-
tion occurring during an immune response 
(Germain and Benacerraf, 1981; Golub, 1981) 
we still know very little about the way in 
which immunomodulating agents may influ-
ence these processes. Preliminary results have 
been reported for some substances, e.g., such 
as dexamethasone (Larsson, 1980), cyclophos-
phamide (Turk and Parker, 1982), ad-
riamycine (Ehrke et al., 1982) and cyclosporin 
A (Britton and Palacios, 1982), but altogether 
our knowledge in the field oE drug-manipu-
lated immune reactivity is still very limited. 
This certainly contributes to the limitation of 
clinical success rates in the treatment of au-
toimmune diseases and graft rejection reac-
tions. The necessity of studying both, phar-
macological as weIl as immunobiological 
parameters in the application of new, but also 
of seemingly established substances in a more 
systematic and clearly comparative way led us 
to design the concept of a combined treatment 
of drug plus alloantigen to establish pharma-
con-antigen-variation-effect (PA VE) pat-
terns. From the two main variables, drug and 
antigen, the influence of the following 
parameters was studied in detail: (1) type of 
drug, (2) time of drug-application in relation 
to the antigen, (3) drug-dosage and (4) state of 
sensitization of the recipient. Although com-
bined treatments have been described by sev-
eral authors (Berenbaum, 1979 j Gaal and 
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Nowotny, 1979; Cottney et al. , 1980; Goto et 
al., 1981; Turk and Parker, 1982), systematic-
comparative immunopharmacological studies 
for the T -cell system have so far not been re-
ported. 
The significance of the investigated im-
munobiological parameters for manipulation 
of immune reactivity according to the PA VE 
described above will be discussed in the fol-
lowing. 
1. Type o[ drug 
Although each drug shows its own distinct 
reaction profile expressing immunostimula-
tion and/or immunosuppression certain 
characteristics of different immunomodulat-
ing drugs appear to correspond to each other. 
This led to their classification into one of the 
six reaction types described in Table 1. These 
reaction types do not correlate exactly with 
the biochemical modes of drug action (e.g. al-
kylating agent, alkaloid, antimetabolite, 
cytostatic antibiotic) although certain correla-
tions are obvious. Thus, reaction type I, the 
"inverted S shape" is found primarily with al-
kylating drugs and antimetabolites, reaction 
type II and III primarily with the vinca al-
kaloids and reaction type VI only with dacar-
bazine. In spite of this, the apriori assumption 
of similar immunomodulating abilities of 
drugs belonging to the same biochemical 
group is not correct. Adequate characteriza-
tion of drugs should thus include both, the 
biochemical as weIl as the immunobiological 
pattern of action. Especially, the hitherto 
often too single classification of drugs as im-
munosuppressive or immunostimulative ap-
pears to require reevaluation. (Furthermore: 
The recent tendency to use the terms im-
munostimulation and immunomodulation 
synonymously may create additional confu-
sion.) 
2. Time o[ drug application 
This parameter appears to be essential for the 
characterization of an immunomodulating 
agent. Only by systematically varying this 
parameter is it possible to establish reaction 
profiles as shown in Figures 1 and 2. These 
may give hints for a distinct manipulation of 
immunoregulation and also for the underlying 
mode of action. Considering that the main ef-
fects of cytostatic drugs cannot simply be as-
sumed to be nonspecific cytotoxicity, it 
should not be too surprising that very few 
drugs (DTIC 1°,2°, FU 2°) show immunosup-
pression throughout the entire period of ap-
plication, as would be expected from general 
impairment of proliferation. Obviously, so-
called cytostatic drugs may weIl affect the im-
mune response not only by differential 
cytotoxicity but also by a distinct interference 
with the immunoregulation. This is seen most 
strikingly with reaction type I in the form of 
strong immunostimulation. 
3. Drug dosage 
Compared with the other parameters investi-
gated, the influence of the drug dosage on the 
reaction profile is surprisingly small. With 
most drugs only slight quantitative differences 
occur, whereas profound qualitative differ-
ences are rare (6-MP 1 0, AM 1°). This result is 
remarkable because other authors have pub-
lished data indicating that the dosage may play 
an important role in the manipulation of the 
immune response (Orsini et al., 1977; Cottney 
et al., 1980). Most authors however, express 
the dosage in terms of mg/kg body weight. In 
pharmacologically adequate terms it is not 
possible to compare results achieved on this 
basis. Therefore, our data, expressing in % of 
the LDso and thus providing information on 
the actual toxicity of the drug in the animal, 
unfortunately allow for direct comparisons al-
most only between the various own findings. 
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4. State o/sensitization References 
Beside the time of drug application, this 
parameter has a crucial influence on the result-
ing re action profiles. Only for MTX, 6-MP 
and DTI C do the re action profiles for 1 ° and 2° 
sensitized mice correspond to each other. In 
contrast, for CY, IF, VLB, VCR, PC, AM 
and FU the reaction profiles change com-
pletely. In the literature too little attention has 
so far been paid to the significance of the state 
of sensitization of the recipient. Experiments 
are nearly always carried out in 1 ° sensitized 
animals, where immune reactivity is built up 
for the first time by the antigen on day O. In a 
presensitized organism however, the antigen 
boosters preestablished immune reactivity 
that will be altered by the application of the 
drug. Differences in the effects of cytostatic 
drugs in 1° and 2° sensitized organisms may 
thus provide information on the ability of a 
drug to interfere differently with different 
subsets of immunologically reactive cells. 
Immunobiological mechanism 0/ drug action 
The modulation of the T -effector cell reactiv-
ity as presented here for the different investi-
gated drugs directly leads to the question of 
the underlying mode of drug action. In view 
of the well-known network of T -regulator 
cells, analysis of this T -effector cell reactivity 
should include investigations of such regulat-
ing cells. Investigations of this kind are at pre-
sent under study. First results indicate that 
some of the drugs not only activate or elimi-
nate specific T -effector cells but also activate 
or eliminate specific resp. nonspecific T -sup-
pressor cells depending on the application of 
the drug before or after the antigen. These pre-
liminary findings are under further study; but 
it may already be stated that they will provide 
further insight into the remarkably differential 
effects of immunomodulating drugs. 
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